
==== Front
PLoS One
PLoS One
plos
PLOS ONE
1932-6203
Public Library of Science San Francisco, CA USA

10.1371/journal.pone.0304485
PONE-D-24-01162
Research Article
Medicine and Health Sciences
Endocrinology
Endocrine Disorders
Diabetes Mellitus
Type 2 Diabetes
Medicine and Health Sciences
Medical Conditions
Metabolic Disorders
Diabetes Mellitus
Type 2 Diabetes
Biology and Life Sciences
Anatomy
Musculoskeletal System
Muscles
Smooth Muscles
Medicine and Health Sciences
Anatomy
Musculoskeletal System
Muscles
Smooth Muscles
Medicine and Health Sciences
Urology
Sexual Dysfunction
Erectile Dysfunction
Research and Analysis Methods
Animal Studies
Experimental Organism Systems
Model Organisms
Mouse Models
Research and Analysis Methods
Model Organisms
Mouse Models
Research and Analysis Methods
Animal Studies
Experimental Organism Systems
Animal Models
Mouse Models
Biology and Life Sciences
Cell Biology
Cellular Types
Animal Cells
Muscle Cells
Smooth Muscle Cells
Biology and Life Sciences
Anatomy
Biological Tissue
Muscle Tissue
Muscle Cells
Smooth Muscle Cells
Medicine and Health Sciences
Anatomy
Biological Tissue
Muscle Tissue
Muscle Cells
Smooth Muscle Cells
Biology and Life Sciences
Physiology
Muscle Physiology
Muscle Contraction
Biology and Life Sciences
Anatomy
Body Fluids
Blood
Blood Sugar
Medicine and Health Sciences
Anatomy
Body Fluids
Blood
Blood Sugar
Biology and Life Sciences
Physiology
Body Fluids
Blood
Blood Sugar
Medicine and Health Sciences
Endocrinology
Endocrine Disorders
Diabetes Mellitus
Medicine and Health Sciences
Medical Conditions
Metabolic Disorders
Diabetes Mellitus
Nesfatin-1 regulates the phenotype transition of cavernous smooth muscle cells by activating PI3K/AKT/mTOR signaling pathway to improve diabetic erectile dysfunction
Nesfatin-1 improve diabetic erectile dysfunction
Chen Keming Data curation Formal analysis Writing – original draft Writing – review & editing 1 2
Huang Bincheng Data curation Validation Writing – review & editing 1
Feng Jiajing Data curation Writing – review & editing 1
Hu Zhengxing Data curation Writing – review & editing 1
Fan Shuzhe Data curation Writing – review & editing 2
Ren Shuai Data curation Writing – review & editing 1
Tian Haifu Data curation Writing – review & editing 1
Abdulkarem M. M. Al-qaisi Mohammed Data curation Writing – review & editing 1
Wang Xuehao Data curation Writing – review & editing 1
Tuo Yunshang Data curation Writing – review & editing 1
Liang Xiaoxia Data curation Writing – review & editing 2
Xie Haibo Data curation Writing – review & editing 2
He Rui Data curation Writing – review & editing 2 *
https://orcid.org/0000-0003-1665-5653
Li Guangyong Data curation Writing – review & editing 1 *
1 Urology Department of General Hospital, Ningxia Medical University, Ningxia, China
2 Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan, China
Silva Fábio Henrique Editor
Sao Francisco University: Universidade Sao Francisco, BRAZIL
Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ruihe515@163.com (RH); guangyongli1979@hotmail.com (GL)
3 9 2024
2024
19 9 e030448510 1 2024
14 5 2024
© 2024 Chen et al
2024
Chen et al
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Objective

This study aims to explore the impact of Nesfatin-1 on type 2 diabetic erectile dysfunction (T2DMED) and its underlying mechanism in regulating the phenotypic switching of corpus cavernosum smooth muscle cells (CCSMCs).

Methods

Twenty-four 4-week-old male C57 wild-type mice were randomly assigned to the control group, model group, and Nesfatin-1 treatment group. Monitoring included body weight, blood glucose levels, and penile cavernous pressure (ICP). Histochemistry and Western blot analyses were conducted to assess the expressions of α-SMA, OPN, and factors related to the PI3K/AKT/mTOR signaling pathway. CCSMCs were categorized into the control group, high glucose and high oleic acid group (GO group), Nesfatin-1 treatment group (GO+N group), sildenafil positive control group (GO+S group), and PI3K inhibitor group (GO+N+E group). Changes in phenotypic markers, cell morphology, and the PI3K/AKT/mTOR signaling pathway were observed in each group.

Results

(1) Nesfatin-1 significantly ameliorated the body size, body weight, blood glucose, glucose tolerance, and insulin resistance in T2DMED mice. (2) Following Nesfatin-1 treatment, the ICP/MSBP ratio and the peak of the ICP curve demonstrated a significant increase. (3) Nesfatin-1 significantly enhanced smooth muscle and reduced collagen fibers in the corpus cavernosum. (4) Nesfatin-1 notably increased α-SMA expression and decreased OPN expression in CCSMCs. (5) Nesfatin-1 elevated PI3K, p-AKT/AKT, and p-mTOR/mTOR levels in penile cavernous tissue.

Conclusions

Nesfatin-1 not only effectively improves body weight and blood glucose levels in diabetic mice but also enhances erectile function and regulates the phenotypic switching of corpus cavernosum smooth muscle. The potential mechanism involves Nesfatin-1 activating the PI3K/AKT/mTOR signaling pathway to induce the conversion of CCSMCs to a contractile phenotype.

http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 81860268,82201000 https://orcid.org/0000-0003-1665-5653
Li Guangyong Ningxia Key Research and Development Project 2023BEG03021;2021BEB04034 https://orcid.org/0000-0003-1665-5653
Li Guangyong Ningxia Natural Science Foundation 2021AAC02025 https://orcid.org/0000-0003-1665-5653
Li Guangyong Ningxia science and technology innovation leading talent training project 2020GKLRLX06,2020GKLRLX11 https://orcid.org/0000-0003-1665-5653
Li Guangyong ,Ningxia Medical University research project XT2019017 https://orcid.org/0000-0003-1665-5653
Li Guangyong This paper is supported by National Natural Science Foundation of China (81860268,82201000),Ningxia Key Research and Development Project (2023BEG03021;2021BEB04034) Ningxia Natural Science Foundation (2021AAC02025), Ningxia science and technology innovation leading talent training project (2020GKLRLX06,2020GKLRLX11),Ningxia Medical University research project (XT2019017).The funders were not involved in study design, data collection and analysis, publication decisions, or manuscript preparation. Data AvailabilityAll relevant data are within the manuscript and its Supporting Information files.
Data Availability

All relevant data are within the manuscript and its Supporting Information files.
==== Body
pmcIntroduction

With the improvement of living standards, the incidence of type 2 diabetes mellitus erectile dysfunction(T2DMED) has increased, which seriously affecting people’s quality of life [1, 2]. However, the current treatment of T2DMED mainly relies on strict diet and effective drug control of blood glucose, correction of dyslipidemia and control of hypertension, at the same time oral phosphodiesterase type 5 inhibitors and penile cavernous drug injection therapy are required to achieve a certain effect.Currently, there is a lack of drugs that can simultaneously control blood glucose and improve erectile dysfunction [3]. The precise mechanism underlying erectile dysfunction resulting from type 2 diabetes remains unclear. This lack of clarity is also responsible for the limited efficacy observed when simply administering drugs to manage blood glucose and address erectile dysfunction in clinical settings.

Penile erection mainly depends on dilating the cavernous artery and cavernous sinus.The contraction and relaxation of corpus cavernosal smooth muscle (CCSMs) determine the expansion of the cavernous sinus and penile erection. Therefore, maintaining the normal function of corpus cavernosal smooth muscle plays a crucial role in improving penile erection and the treatment of T2DMED. Studies have shown that the smooth muscle phenotype is an important factor in maintaining the function and structure of smooth muscle, and regulating the phenotype of corpus cavernosum smooth muscle to the contractile type can improve the occurrence of ED [4]. At present, a large number of literature confirmed hypoxia [5–7], platelet-derived growth factor [8], chronic prostatitis [9], tobacco harmful gas [10], and other external factors may lead to the transition of CCSMs phenotype to synthetic phenotype, and then lead to ED. Diabetes hyperglycemia is also an important factor leading to smooth muscle phenotype switching [11], however, it is rarely reported in T2DMED.

Nesfatin-1 is a newly discovered secretory peptide found in the hypothalamus, brain stem, and gastrointestinal tract. It is a hydrolytic fragment of the nuclear group of protein 2 (NUCB2). In recent years, as research on diabetes-related complications has advanced, the role of Nesfatin-1 as a novel peptide molecule has gained widespread recognition. It has been acknowledged for its ability to enhance glucose metabolism, reduce blood glucose levels, regulate cardiovascular function, and consequently, ameliorate diabetes complications along with associated structural and functional abnormalities in organs [12–14]. Current studies have confirmed that Nesfatin-1 can improve diabetic cardiomyopathy [15], diabetic nephropathy [16], diabetic retinopathy [17], diabetic polycystic ovary syndrome [18, 19] and other diseases,which is considered as one of the important potential target drugs for the treatment of diabetes-related complications [20]. However, there have been no reports on whether Nesfatin-1 can improve Type 2 Diabetes Mellitus Erectile Dysfunction (T2DMED) and its specific mechanism. Therefore, this study aims to investigate the potential of Nesfatin-1 to improve T2DMED and elucidate its mechanism by examining the regulation of Nesfatin-1 on the phenotype switching of cavernous smooth muscle cells. The objective is to offer new insights for the clinical treatment of T2DMED.

Materials and methods

1. Experimental materials and instruments

1.1. Experimental animals and cell culture

Twenty-four SPF grade 4-week-old wild-type C57BL/6J male mice weighing about 20g±3g were purchased from the Laboratory Animal Center of Ningxia Medical University. (Certificate number:SCXK2020-0001).Feeding conditions: constant temperature and humidity, 12 hours of light alternating daily, free feeding and drinking, quiet environment. Corpus cavernosum smooth muscle cells (CCSMCs) (Item No. CP-M218), Purchased from Wuhan Punosai Company. The first 5 generations of cultured cells were used in the experiment.

1.2. Experimental reagents and instruments

High-fat Diets were obtained from Research Diets, USA (60 Kcal% Fat,Lot number:D12492; Nesfatin-1 (Item No.H-003-22) purchased from Phoenix (Burlingame, CA, USA); Immunohistochemical reagents were purchased from Beijing Zhongshan Jinqiao Biotechnology Development Co.LTD.OPN, α-SMA, PI3K, AKT, p-AKT, mTOR, p-mTOR antibodies and goat anti-rabbit and mouse antibodies secondary antibodies were purchased from Affinity Biosciences. Oleic acid (Item No. HY-N1446), Esculetin (Item No. HY-NO284); Sildenafil (Item No. HY-15025, 10mM), all bought in MCE company.

2. Experimental methods

2.1 Animal experiments

2.1.1. Animal models were established and grouped. Twenty-four 4-week-old wild-type C57BL/6J male mice weighing about 20g±3g were randomly divided into Control group, Model group, and Nesfatin-1 treatment group, with 8 mice in each group.The control group was fed with a normal diet, and the model group and Nesfatin-1 treatment group were fed with a 60% high-fat diet for 16weeks. After 16weeks, Nesfatin-1 treatment group was intraperitoneally injected with Nesfatin-1 (8nM/kg) for 4 weeks, and model group was fed with high-fat diet for 4 weeks.All animal experiments were approved by the Ethics Committee of Ningxia Medical University.

2.1.2. Body mass, Blood glucose monitoring, and intracavernous pressure (ICP) measurement were performed. Body mass:The body mass of mice was monitored every 7 days during the same time period to analyze body mass changes.blood glucose:Oral glucose tolerance test (OGTT): After fasting for 16-18h before sampling, the mice were given 3g/kg glucose solution by gavage, and blood glucose was measured at 0min, 15mins, 30mins, 60mins, 90mins, and 120mins. The changes of blood glucose and the area under the curve (AUC) were recorded and analyzed [21]. Insulin tolerance test (ITT): After fasting for 5 hours for 2 days before sampling, the body weight was measured, and the blood glucose was measured at 0min, 15mins, 30mins, 60mins, and 120mins after intraperitoneal injection of insulin (1 IU/kg), and the AUC was analyzed.

2.1.3. Intracavernous pressure (ICP): After the mice were anesthetized with 2% pentobarbital sodium 45mg/kg and routinely sterilized. The foreskin and tunica albuginea were separated, and the subcutaneous fat and connective tissue were free until the penile cavernous nerve was obviously exposed. A platinum bipolar electrode was connected to an electrical stimulator, and the cavernous nerve was stimulated at 5V for 1min. The changes of intracavernous pressure during electrical stimulation were observed and recorded. The mean systemic blood pressure (MSBP) and the maximum intracavernous pressure (ICP) during the stimulation of the erectile nerve were measured and the ratio of ICP to MSBP was compared to evaluate the erectile response.

2.1.4. The level of glycosylated hemoglobin (HbA1c) in serum was detected by ELISA. Serum samples of mice in each group were collected, and anticoagulant was added and centrifuged. The levels of glycosylated hemoglobin (HbA1c) in serum samples of mice in each group were detected by ELISA method, and the operation steps were strictly according to the instructions in the kit.

2.1.5. Immunohistochemical staining:After dewaxing and entry, the paraffin sections were rinsed 3 times with PBS, and then the antigen was repaired with 0.01mol/L citrate buffer for 15minutes. After natural cooling for 2h, the sections were rinsed again, and the surface was covered with endogenous peroxidase blocker for 30mims. After rinsing, the sections were blocked with goat serum at room temperature for 1h, and the primary antibody was dropped and then blocked at 4°C overnight. The next day, a secondary antibody was added after rewarming for 30minutes, incubated at room temperature for 1h, and DAB was used for color development. After color development was completed, the slides were stained with hematoxylin solution for 4minutes, differentiated with 1% hydrochloric acid alcohol, flushed for 15minutes, and sealed with neutral resin after routine dehydration.

2.1.6. Animal tissues were detected by western blotting. After a freezing mill fully ground the penile tissue, the supernatant was taken, and the protein was extracted from the penile tissue of mice by the NDA/RNA/Protein Kit (Item No. R6734-01, omega Company). The protein concentration was measured according to the instructions of the BCA protein detection kit, and the loading volume was calculated. Electrophoresis at 80V voltage was followed by a 200mA electric transfer of 150mims. After blocking with 5% skim milk for 2h, the primary antibody was incubated at 4°C overnight, and the next day, the secondary antibody was incubated at room temperature for 2h. Images were acquired after exposure and quantified for analysis.

2.2. Cell experiments

2.2.1. Culture and processing of mouse corpus cavernosum smooth muscle cells (CCSMCs). CCSMCs were routinely cultured in DMEM/F12 substrate containing 10%FBS.

2.2.2. Cell proliferation was determined by CCK-8 assay to select each drug’s treatment time and concentration. CCSMCs were routinely cultured and treated with Nesfatin-1 at concentrations of 0ng/ml, 50ng/ml, 100ng/ml, 150ng/ml, 200ng/ml, 250ng/ml and 300ng/ml. Oleic acid at Concentration of 0nM, 2.5nM, 5nM, 10nM, 15nM, 20nM. The concentration of Esculetin was 0μM, 10μM, 20μM, 30μM, 40μM; Each drug and concentration were set up 0h, 12h, 24h, 48h, 72h time gradient. Combined with the previous experiments, the concentration and time with the greatest change in cell OD were selected for further experiments.

2.2.3. Cellular immunofluorescence staining experiments. CCSMCs were cultured on cover slides. When the density reached 90%, it was fixed in 4% paraformaldehyde for 30mins, translatated with 0.3% Triton X-100 for 20mins, sealed with 5% BSA for 1h, the primary antibody was incubated at 4°C overnight, and the secondary antibody was incubated with fluorescein labeled at room temperature for 2h, and then sealed with DAPI-containing tablets.

2.2.4. Western blot was used to detect the expression of corresponding proteins in CCSMCs. The grouped treated cells were fully lysed with RIPA lysate for 30mims, adherent cells were treated with a cell scraper, centrifuged, and the supernatant was removed for determination of protein concentration by BCA and fixed with Buffer. Electrophoresis was performed at 80V with a 200mA electrotransfer and blocked with skim milk. The primary antibody was incubated at 4°C overnight, and the secondary antibody was incubated for 2h. After exposure, images were acquired and quantified for analysis.

3. Statistical methods

Graph Pad Prism 9.0 software was used to analyze the experimental results. Data were expressed as mean± standard deviation (mean±SD). One-way variance analysis was used for comparison of means between groups, and the Dunnett test was used for pairwise comparison of homogeneity of variance. P<0.05 was considered statistically significant.

Results

1. The type 2 diabetes mellitus erectile dysfunction (T2DMED) mouse model was induced through a 16-week high-fat feeding protocol

The exogenous administration of Nesfatin-1 demonstrated an improvement in the body weight and glucose metabolism indices of the T2DMED mice

After 16 weeks of high-fat feeding, the mice became fatter, weight increased significantly, and fasting blood glucose increased.The results of oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) showed that blood glucose was significantly higher than that of normal control group at 15, 30, 60 and 120 minutes. Exogenous give Nesfatin-1 4 weeks after treatment, body size, body weight in mice, significantly reduced fasting glucose (Fig 1A–1C) (Body mass:Control group: 31.56±1.6g; Model group: 57.0±2.2g; Nesfatin-1 group: 41.1±2.2g. Fasting blood glucose: Control group:5.0±0.5; Model group:9.4±1.5; Nesfatin-1 group:5.7±0.2). Glycated hemoglobin (HbA1c) levels compared with model group significantly reduced (Control group: 4.9μ±1.4mol/ml; Model group: 11.1μ±3.1mol/ml; Nesfatin-1 group: 3.2μ±0.5mol/ml). OGTT and TII results of mice treated with Nesfatin-1 were significantly improved.The oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) showed that blood glucose levels were significantly higher at 15, 30, 60, and 120 minutes compared to the control group. After 4 weeks of Nesfatin-1 treatment, the OGTT and ITT results in the treatment group significantly decreased (Fig 1D–1E), with statistically significant differences (P<0.05). Additionally, the level of glycated hemoglobin (HbA1c) after Nesfatin-1 treatment was significantly lower than the model group (P<0.05) (Fig 1C) (Control group: 4.9μ±1.4mol/ml; Model group: 11.1μ±3.1mol/ml; Nesfatin-1 group: 3.2μ±0.5mol/ml). with statistically significant differences (P<0.05).

10.1371/journal.pone.0304485.g001 Fig 1 Changes in metabolism-related indicators in mice.

a.Changes in the mouse body size; b.Changes in mice body mass; c.Changes of fasting blood glocuse in each group of mice; d.Changes of HbA1c in each group of mice; e.Changes in OGTT value and AUC in each group of mice; f.Changes in ITT value and AUC in each group of mice. (OGTT:Oral glucose tolerance test; ITT:Insulin tolerance test;AUC:area under the curve; n = 5 per group, *P<0.05).

2. T2DMED mice, subjected to a high-fat diet for 16 weeks, exhibited the development of erectile dysfunction

Notably, the exogenous administration of Nesfatin-1 significantly ameliorated erectile dysfunction in T2DMED mice

The peak value of the ICP curve in normal mice was 155±13.1cmH2O, and the mean value of ICP/MSBP was 0.90±0.05, while the peak value of ICP curve in T2DMED mice was significantly reduced to 80±22cmH2O, and the mean value of ICP/MSBP was 0.49±0.13. The difference was statistically significant (P < 0.05). After Nesfatin-1 treatment, the peak value of ICP curve in mice increased significantly and the ICP curve became steeper (Fig 2A). The average peak value of the curve was 154.4±16.1cmH2O, and As the average of ICP/MSBP was 0.9±0.04. Further statistical comparison of ICP/MSBP showed statistical differences among the three group (Fig 2B) (P<0.05).

10.1371/journal.pone.0304485.g002 Fig 2 The changes of erectile function in mice.

a.ICP curves in mice. b.Changes in the ratio of ICP/MSBP of mice in each group. (ICP:Intracaversal pressure; MSBP:Systemic blood pressure (MSBP);n = 4 per group *P<0.05).

3. Nesfatin-1 increases the smooth muscle content of T2DMED mice

Masson staining was used to observe the changes of in smooth muscle and collagen fibers in the corpus cavernosum. We found that the smooth muscle fibers in T2DMED mice were significantly less than those in the control group, and the content of collagen fibers was significantly increased. After 4 weeks of Nesfatin-1 treatment, the smooth muscle increased and the collagen fibers decreased (Fig 3A and 3B), with statistically significant differences (P<0.05).

10.1371/journal.pone.0304485.g003 Fig 3 The content of smooth muscle fibers and collagen in mice.

a. Masson staining results in each group of mice. (up bar: 200μm; down bar:100μm); b.Changes in the ratio of smooth muscle fiber to collagen fiber content in mice. (n = 4 per group *P<0.05).

4. Nesfatin-1 regulates the corpus cavernosal smooth muscle phenotype in T2DMED mice

Immunohistochemistry showed that α-SMA, a marker of smooth muscle contraction phenotype, significantly decreased in T2DMED mice and increased significantly after Nesfatin-1 treatment. However, the synthetic phenotypic marker OPN was significantly increased in the model group and decreased significantly by Nesfatin-1 treatment (Fig 4A and 4B). Further quantitative analysis of α-SMA and OPN by Western blot showed that the change trend was consistent with the results of immunohistochemistry (Fig 4C and 4D).

10.1371/journal.pone.0304485.g004 Fig 4 The expression of phenotypic markers in mice.

a.Immunohistochemical micrographs and quantitative analyses of α-SMA in mice; b.Immunohistochemical micrographs and quantitative analyses of OPN in mice; (up bar: 200μm; down bar: 100μm); c.The level ofα-SMA and OPN in penile cavernous tissue of mice was determined by Western blot; d.Quantitative analysis of α-SMA and OPN by Western blot. (n = 4 per group *P<0.05).

5. Nesfatin-1 regulates the PI3K/AKT/mTOR signaling pathway

The protein level PI3K, p-AKT/AKT and p-mTOR/mTOR in the penile cavernous tissue of mice was remarkably decreased in T2DMED(P<0.05). Compared to the model group, the level of PI3K, p-AKT/AKT and p-mTOR/mTOR in penile cavernous tissue was remarkably increased in the treatment group(P<0.05). Western blot results and quantitative analysis of gray values of bands showed that the PI3K was inhibited in T2DMED mice, and the phosphorylation levels of its downstream factors AKT and mTOR were also significantly decreased, but the total AKT and mTOR did not change. After Nesfatin-1 treatment, PI3K was significantly activated in the treatment group, and its downstream p-Akt and p-mtor were also significantly increased(P<0.05), but there was no significant difference in the total AKT and mTOR levels(Fig 5A and 5B).

10.1371/journal.pone.0304485.g005 Fig 5 Effect of PI3K/AKT/mTOR signaling pathway on phenotypic switching of corpus cavernosum smooth muscle.

a.The level of PI3K,p-AKT,AKT, p-mTOR and mTOR in the penile cavernous tissue of mice was determined by Western blot. b.Quantitative analysis of PI3K,p-AKT,AKT, p-mTOR and mTOR in each group(n = 4 per group *P<0.05).

6. The cell model was established through co-culture with high glucose and high oleic acid

Sildenafil, Nesfatin-1, and Esculetin were administered to observe their effects on the morphology and quantity of CCSMCs

CCSMCs were detected by CCK-8 experiment according to the corresponding drug concentration gradient and time gradient, and the corresponding optical density (OD) value of each hole measured at 450nm was determined. The results showed that the concentration of Acid oil was 20mM; The concentration of Nesfatin-1 at 150ng/mL; Esculetin at 40μM and treated separately for 48 hours had the greatest effect on OD values (Fig 6A). Therefore, we selected the drug concentration and treatment time for subsequent experiments.

10.1371/journal.pone.0304485.g006 Fig 6 CCK-8 results of oleic acid, nesfatin-1 and Esculetin and micrographs of corpus cavernosum smooth muscle cells in each group after treatment.

a.DO values of oleic acid, nesfatin-1, and Esculetin in cck-8 assay. b.Micrographs of spongy smooth muscle cells in each group after 48 hours of treatment. (magnification:400X).

CCSMCs were divided into groups according to the drug concentration and treatment time selected by CCK-8 assay, and pictures of each group were taken by inverted microscope camera system. CCSMCs treated with high glucose and high oleic acid were round in shape and decreased in number. After Nesfatin-1 and Sildenafi treatment, most of the cells returned to spindle shape and their number increased significantly. There was no significant difference in cell morphology and number between Nesfatin-1 and Sildenafi treatment groups. However, after treatment with PI3K/AKT inhibitor Esculetin, the morphology of CCSMCs returned to the main round shape and the number of CCSMCS decreased significantly. (Fig 6B)

7. Through in vitro cell experiments, it has been confirmed that Nesfatin-1 regulates the transformation of CCSMCs into a contractile type, with the PI3K/AKT/mTOR signaling pathway playing a crucial role in this process

Immunofluorescence indicated that α-SMA expression decreased significantly in GO group, while OPN expression increased significantly and its shape changed from spindle to round. After Nesfatin-1 and Sildenafi treatment, α-SMA increased significantly, OPN decreased significantly, and cell morphology returned to a spindle shape. However, α-SMA expression was not significantly increased and OPN expression was not significantly decreased in the GO+N+E group, showing a trend similar to that in the GO group (Fig 7A and 7B). We quantitatively analyzed α-SMA and OPN of cells in each group by Western blot, and the change trend was consistent with the immunofluorescence results (Fig 7C and 7D). We quantitatively analyzed the PI3K/AKT/mTOR signaling pathway expression of CCSMCs in each group by Western blot. The results indicated that the expressions of p-AKT/AKT and p-mTOR/mTOR were significantly increased in CCSMCs treated after Nesfatin-1 and Sildenafi treatment (P<0.05). However, the expressions of p-AKT/AKT and p-mTOR/mTOR in the GO+N+E group were significantly decreased compared with those in GO+N and GO+S groups (P<0.05), showing a trend similar to that in the GO group (Fig 7E and 7F).

10.1371/journal.pone.0304485.g007 Fig 7 The expression changes of CCSMCs phenotypic markers and PI3K/AKT/mTOR signaling pathway.

a. α-SMA expression in CCSMCs by immunofluorescence (Bar 50μm); b:OPN expression in CCSMCs by immunofluorescence.(Bar 50μm); c.The level ofα-SMA and OPN in penile cavernous tissue of mice were determined by Western blot; d.Quantitative analysis of α-SMA,OPN in each group;e.The level of PI3K,p-AKT,AKT, p-mTOR and mTOR in the penile cavernous tissue of mice was determined by Western blot;f.Quantitative analysis of PI3K,p-AKT,AKT, p-mTOR and mTOR in each group.(n = 4 per group *P<0.05).

Discussion

Currently, more than half of diabetes patients worldwide are suffering from erectile dysfunction (ED), and diabetes is gradually recognized as an important cause of ED [21, 22] The clinical treatment of diabetes-related erectile dysfunction mainly relies on basic therapies such as dietary control, hypoglycemic medication, combined with oral phosphodiesterase type 5 inhibitors (tadalafil/sildenafil, etc.) and penile cavernosal injection to improve erectile dysfunction However, in clinical treatment, there are still a considerable number of patients who do not respond well to these medications [23], and the lack of both can improve diabetes and can improve ED drugs. At present, the specific mechanism of erectile dysfunction caused by type 2 diabetes mellitus (T2DM) remains unclear, which is also the reason the poor effect of simply drugs to control blood glucose and treating erectile dysfunction with drugs is not satisfactory in clinical practice. Therefore, it is urgent to explore the mechanism of T2DMED, explore new drugs and new targets for improving T2DMED, and provide a new treatment idea for T2DMED patients.We through the establishment of T2DMED mouse model and exogenous Neisfatin ‐ 1 treatment. We found that the body weight, blood glucose, insulin resistance and erectile function of the treated mice were significantly decreased, and the expression of contractile phenotypic marker α-SMA was increased, while the synthetic phenotypic marker OPN was decreased, the corpus cavernosum smooth muscle fibers were increased, and PI3K/AKT/mTOR signaling pathway was activated.We established an in vitro model of spongy smooth muscle cultured with high oleic acid and high glucose and treated it with Nesfatin 1. We found that the CCSMCs phenotype changed to contractile after treatment, and the PI3K/AKT/mTOR signaling pathway was activated. After we added Esculetin to inhibit PI3K/AKT signaling pathway, the expression of α-SMA was significantly decreased and the expression of OPN was increased in corpus cavernosum smooth muscle cells. The effect of Nesfatin-1 on improving the phenotype switching of CCSMCs was significantly inhibited, which further demonstrated that Nesfatin-1 regulated the phenotype switching of CCSMCS through PI3K/AKT/mTOR signaling pathway.

Some studies have reported the use of the streptozotocin (STZ) injection method to induce diabetic erectile dysfunction in animal models, where the destruction of pancreatic islet cells leads to diabetes [24–27]. However, this approach does not align with the clinical epidemiological characteristics, given that type 2 diabetes mellitus is more prevalent in practical medical settings.In our research, we adopted a well-recognized modeling technique by continuously feeding mice with a high-fat diet for 16 weeks to establish a mouse model that closely mimics the disease characteristics and metabolic status of type 2 diabetes mellitus. Evaluation of relevant indicators of glucose metabolism in the model group revealed a significant increase in body weight, body type, and blood glucose values compared to the control group, showing statistically significant differences (P<0.05).Subsequently, we measured the intracavernous pressure (ICP) in the mice. The ICP of the mice in the model group decreased, manifesting the typical characteristics of the Type 2 Diabetes Mellitus Erectile Dysfunction (T2DMED) model. This outcome indicated that mice with type 2 diabetes mellitus induced solely by a high-fat diet would exhibit an erectile dysfunction phenotype, affirming the successful establishment of the T2DMED model.

We delved deeper into understanding the mechanism behind Type 2 Diabetes Mellitus Erectile Dysfunction (T2DMED). Penile erection is mainly regulated by the cavernous sinus of the penis, which is mainly composed of cavernous endothelial cells and smooth muscle cells. When the cavernous sinus is congested, it leads to the expansion of the cavernous body of the penis and produces an important mechanism of erection [28].We further explored the mechanism of T2DMED. At present, a large number of studies have reported that the dysfunction of cavernous endothelial cells leads to the occurrence of ED [29], but they have neglected that cavernous smooth muscle is the main tissue component responsible for controlling blood flow into the corpus cavernosa and causing erectile tissue. The regulation of cavernous smooth muscle phenotype is an important factor affecting cavernous function.The phenotypes of cavernous smooth muscle cells (CCSMCs) can be categorized into contractile and synthetic types. Contractile CCSMCs exhibit considerable plasticity, allowing them to undergo phenotypic regulation from a contractile state to a synthetic state in response to local environmental stimul [30]. The characteristic of smooth muscle cell transition to the synthetic phenotype is an increase in expressions of extracellular matrix and type I collagen, while the expressions of contractile cytoskeletal proteins (such as α-SMA, SM22α, etc.) decrease and the expressions of synthetic cytoskeletal proteins (such as OPN, tenascin-C, etc. [31]). The main component of contractile smooth muscle cells is myofilament, which is an important factor in maintaining smooth muscle contraction function. The synthetic phenotype has a strong ability to synthesize extracellular matrix, manifesting as excessive proliferation and fibrosis of smooth muscle cells, which can cause contractile dysfunction..Our study found that type 2 diabetes mellitus leads to a significant reduction of α-SMA and a significant increase of OPN in corpus cavernosum smooth muscle cells, which is consistent with the transformation of corpus cavernosum smooth muscle cells into synthetic cells, which may be the mechanism of type 2 diabetes mellitus leading to ED.

In recent years, the significant role of Nesfatin-1 in regulating blood glucose and improving diabetes-related complications has been widely reported [14, 32]. Previous studies have found that Nesfatin-1 can improve obesity-related type 2 diabetes and ameliorate atherosclerosis in the cardiovascular system [33].

Therefore, we speculate that Nesfatin-1 may improve T2DMED while improving type 2 diabetes. Therefore, we hypothesize that Nesfatin-1 may not only improve type 2 diabetes but also alleviate T2DMED. Thus, we attempted to investigate the role of Nesfatin-1 in improving T2DMED and its specific mechanism using the T2DMED mouse model. Through exogenous administration of Nesfatin-1 to the model mice, we observed a significant reduction in blood glucose, body weight, and body size, coupled with improvements in diabetes-related characteristics, effectively correcting metabolic disorders in mice. Even more surprisingly, we found a significant improvement in erectile dysfunction in mice treated with Nesfatin-1, confirming the potential of Nesfatin-1 as a therapeutic option for T2DMED.

In further mechanistic exploration, our investigation revealed that Nesfatin-1 treatment in T2DMED mice resulted in an increase in the number of smooth muscle fibers, a significant upregulation in the expression of the contractile phenotype marker, and a substantial improvement in the contractility of the penile cavernosum. These findings suggest that Nesfatin-1 has the capacity to reduce α-SMA and increase OPN, inducing a transformation in the synthetic phenotype of corpus cavernosum smooth muscle towards the contractile phenotype. Consequently, this restoration of the normal contractile function of corpus cavernosum smooth muscle is indicative of the therapeutic potential of Nesfatin-1 in T2DMED.Studies [34] have pointed out that impaired NO activity released by cavernous endothelial cells is an important cause of erectile dysfunction, and excessive damage of NO to cavernous endothelial cells under pathological conditions is the main mechanism of ED induced by NO-CGMP pathway. cGMP acts as a second messenger to regulate Ca2+ channels, inhibit calcium influx, reduce intracellular calcium concentration, and thus induce relaxation of corpus cavernosum smooth muscle, which is one of the mechanisms of cGMP regulating erectile function. Usually in the diabetic state, NO bioactivity is impaired and the formation of cGMP is limited, resulting in the failure of normal relaxation of corpus cavernosum smooth muscle, which may be one of the reasons for the difficulty in routine treatment of ED in diabetic patients [35]. However, other data suggest that it is at least partially independent of the NO-cgmp pathway [36, 37]. In another study, experimentalshad combined drugs with different NO-binding sites in rat and rabbit models of erectile dysfunction similarly stimulated cGMP production and induced relaxation of cavernous smooth muscle and penile erection independent of NO [38, 39]. This suggests that there are other pathways besides the NO-cGMP pathway that regulate the contraction and relaxation of cavernous smooth muscle. Therefore, exploring a new regulatory pathway is of great significance to improve the clinical treatment of diabetic erectile dysfunction. As a downstream regulator of the classical PI3K/AKT signaling pathway, mTOR has been widely recognized to participate in the regulation of glucose metabolism and energy metabolism. In our previous study, we found that the phosphorylation level of mTOR was significantly inhibited in type 2 diabetic mice induced by HFD.Mu Y et al. came to the same conclusion as us [40]. Similarly, in the context of a high-fat diet-induced model Michelet X et al. also found reduced expression of the mTOR signaling pathway [41].We used PI3K/AKT/mTOR signaling pathway to further explore its possible mechanism in regulating the phenotypic switching of corpus cavernosum smooth muscle. We found that regardless of the inhibition of PI3K/AKT/mTOR signaling pathway and the conversion of cavernous smooth muscle phenotype to synthetic phenotype in the model mice, the PI3K/AKT/mTOR signaling pathway was significantly activated and the expression of contractile phenotype markers was significantly increased after Nesfatin-1 treatment. In a study on phenotypic transformation of vascular smooth muscle, Shui-Bo Zhu [40] et al. demonstrated that activation of PI3K/AKT signaling pathway would promote the transformation of smooth muscle to contractile phenotype and improve smooth muscle function. This is consistent with our conclusion.

To validate our findings, we conducted in vitro cell experiments. We cultured cavernous smooth muscle cells in a high-glucose and high-oleic acid environment to simulate the microenvironment of diabetic metabolic disorder. Our observations revealed that corpus cavernosum smooth muscle cells exhibited a synthetic phenotype consistent with those from type 2 diabetic mice when exposed to a culture environment with high oleic acid and high glucose. After Nesfatin-1 intervention, there was a transformation from a synthetic to a contractile type.

Upon further exploration of the mechanism, we observed that the PI3K/AKT/mTOR signaling pathway was significantly inhibited. In spongy smooth muscle cells cultured with high oleic acid and high glucose, α-SMA expression was significantly decreased, and OPN expression was significantly increased. Following Nesfatin-1 treatment, p-AKT and p-mTOR significantly increased, activating the PI3K/AKT/mTOR signaling pathway. Simultaneously, α-SMA expression significantly increased, and OPN expression significantly decreased.

To further confirm the role of the signaling pathway, we introduced Esculetin to Nesfatin-1 treated cells to directly inhibit the PI3K/AKT/mTOR signaling pathway. We found that Nesfatin-1 significantly inhibited the improvement of phenotype switching in cavernous smooth muscle cells. This further substantiates that Nesfatin-1 regulates the phenotypic switching of CCSMCs through the PI3K/AKT/mTOR signaling pathway.

In recent years, there has been a growing body of research on the role of the star protein Nesfatin-1. Most of these studies have focused on the significant impact of Nesfatin-1 on improving diabetes and obesity [38]. Currently, there is a lack of research investigating the role of Nesfatin-1 in the treatment of type 2 diabetes-related erectile dysfunction (T2DMED). Erectile dysfunction, as a complication of type 2 diabetes, is associated with type 2 diabetes but also has independent pathological mechanisms. Whether Nesfatin-1 can ameliorate T2DMED and the mechanisms involved present crucial scientific questions.This study employed a high-fat feeding approach to establish a type 2 diabetes mouse model, confirming the occurrence of T2DMED. Leveraging cell experiments to simulate the glucose and lipid metabolism microenvironment of corpus cavernosum smooth muscle cells in type 2 diabetes, Nesfatin-1 was introduced for intervention and investigation. The findings demonstrate that Nesfatin-1 not only improves T2DMED but also plays a crucial role in the phenotypic transformation of corpus cavernosum smooth muscle cells.

Supporting information

S1 File (PDF)

S1 Raw images (PDF)

10.1371/journal.pone.0304485.r001
Decision Letter 0
Silva Fábio Henrique Academic Editor
© 2024 Fábio Henrique Silva
2024
Fábio Henrique Silva
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
19 Feb 2024

PONE-D-24-01162Nesfatin-1 regulates the phenotype transition of cavernous smooth muscle cells by activating PI3K/AKT/mTOR signaling pathway to improve diabetic erectile dysfunctionPLOS ONE

Dear Dr. Li,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 04 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Fábio Henrique Silva, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service.

Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free.

Upon resubmission, please provide the following:

The name of the colleague or the details of the professional service that edited your manuscript

A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file)

A clean copy of the edited manuscript (uploaded as the new *manuscript* file)

3. Thank you for stating the following financial disclosure:

“This paper is supported by National Natural Science Foundation of China (81860268,82201000),Ningxia Key Research and Development Project (2023BEG03021;2021BEB04034) Ningxia Natural Science Foundation (2021AAC02025), Ningxia science and technology innovation leading talent training project (2020GKLRLX06,2020GKLRLX11),Ningxia Medical University research project（XT2019017).”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This paper is supported by National Natural Science Foundation of China (81860268,82201000),Ningxia Key Research and Development Project (2023BEG03021;2021BEB04034) Ningxia Natural Science Foundation (2021AAC02025), Ningxia science and technology innovation leading talent training project (2020GKLRLX06,2020GKLRLX11),Ningxia Medical University research project（XT2019017).”

We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This paper is supported by National Natural Science Foundation of China (81860268,82201000),Ningxia Key Research and Development Project (2023BEG03021;2021BEB04034) Ningxia Natural Science Foundation (2021AAC02025), Ningxia science and technology innovation leading talent training project (2020GKLRLX06,2020GKLRLX11),Ningxia Medical University research project（XT2019017).”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

6. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

7. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

8. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors examine the effect of a high-fat diet-induced type 2 diabetes on erectile function (T2DMED) through the PI3K/AKT/mTOR signaling pathway and explore the impact of Nesfatin-1 on T2DMED and its underlying mechanism in regulating the phenotypic switching of corpus cavernosum smooth muscle cells (CCSMCs). They conclude that Nesfatin-1 enhances erectile function by activating the PI3K/AKT/mTOR signaling pathway to induce the conversion of CCSMCs to a contractile phenotype. The study is potentially interesting, but several concerns are listed in detail below.

Comments

1- Previous studies have shown that HFD results in erectile dysfunction through impaired endothelial function and the NO-cGMP pathways, which are the primary mechanisms for erection. Additionally, PI3-kinase/Akt activates eNOS and physiologically mediates erection. I am surprised the authors did not investigate the effect of Nesfatin-1 on the pAKT-NO-cGMP pathway in this study. Please discuss.

2- There was a significant decrease in body weight after Nesfatin-1 treatment in HFD mice. Did the authors measure how much food the HFD mice + treatment group consumed compared to the HFD group?

3- Did the authors consider using an additional control group that was given less HFD food without Nesfatin-1 treatment to see whether the effect of Nesfatin-1 is only related to treatment, not weight loss?

4- Please discuss why the authors did not use esculetin for in vivo experiments.

5- HFD can activate the mTOR signaling pathway as an upstream mediator of NADPH oxidase in the corpus cavernosum. Please discuss.

6- Lastly, the discussion needs a revision. The authors should summarize the key findings in the first paragraph and interpret the results in the following paragraphs, referencing previous conclusions in the literature.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Serkan Karakus

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0304485.r002
Author response to Decision Letter 0
Submission Version1
11 Apr 2024

Our manuscript has been modified in accordance with the requirements of independent reviewers, and the revised version and item-by-item replies to reviewers have been uploaded as required, and the original data has been uploaded as a separate file. Please refer to Mr. Editor.

Attachment Submitted filename: Response to reviewers .doc

10.1371/journal.pone.0304485.r003
Decision Letter 1
Silva Fábio Henrique Academic Editor
© 2024 Fábio Henrique Silva
2024
Fábio Henrique Silva
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
14 May 2024

Nesfatin-1 regulates the phenotype transition of cavernous smooth muscle cells by activating PI3K/AKT/mTOR signaling pathway to improve diabetic erectile dysfunction

PONE-D-24-01162R1

Dear Dr. Guangyong,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Fábio Henrique Silva, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

10.1371/journal.pone.0304485.r004
Acceptance letter
Silva Fábio Henrique Academic Editor
© 2024 Fábio Henrique Silva
2024
Fábio Henrique Silva
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
24 Jun 2024

PONE-D-24-01162R1

PLOS ONE

Dear Dr. Li,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Fábio Henrique Silva

Academic Editor

PLOS ONE
==== Refs
References

1 Malavige L. S. & Levy J. C. Erectile Dysfunction in Diabetes Mellitus. J SEX MED. 6 , 1232–1247 (2009). doi: 10.1111/j.1743-6109.2008.01168.x 19210706
2 Chew K. K. , Earle C. M. , Stuckey B. G. , Jamrozik K. & Keogh E. J. Erectile Dysfunction in General Medicine Practice: Prevalence and Clinical Correlates. INT J IMPOT RES. 12 , 41–45 (2000). doi: 10.1038/sj.ijir.3900457 10982311
3 Gandhi J. et al . The Role of Diabetes Mellitus in Sexual and Reproductive Health: An Overview of Pathogenesis, Evaluation, and Management. CURR DIABETES REV. 13 , 573–581 (2017). doi: 10.2174/1573399813666161122124017 27875946
4 Zeng Q. et al . [Exogenous Hydrogen Sulfide Improves Erectile Dysfunction by Inhibiting Apoptosis of Corpus Cavernosum Smooth Muscle Cells in Rats with Cavernous Nerve Injury]. Nan Fang Yi Ke Da Xue Xue Bao. 39 , 1329–1336 (2019). doi: 10.12122/j.issn.1673-4254.2019.11.10 31852640
5 Zhang X. et al . The Protective Effect of Salidroside On Hypoxia-Induced Corpus Cavernosum Smooth Muscle Cell Phenotypic Transformation EVID-BASED COMPL ALT. 2017 , 3530281 (2017). doi: 10.1155/2017/3530281 28798798
6 Lv B. et al . Phenotypic Transition of Corpus Cavernosum Smooth Muscle Cells Subjected to Hypoxia. CELL TISSUE RES. 357 , 823–833 (2014). doi: 10.1007/s00441-014-1902-0 24913687
7 Chen S. et al . Hypoxia-Induced Phenotypic Transformation of Corpus Cavernosum Smooth Muscle Cells After Cavernous Nerve Crush Injury by Down-Regulating P38 Mitogen-Activated Protein Kinase Expression. SEX MED-UK. 7 , 433–440 (2019). doi: 10.1016/j.esxm.2019.08.005 31540881
8 Yan J. F. et al . The Platelet-Derived Growth Factor Receptor/Stat3 Signaling Pathway Regulates the Phenotypic Transition of Corpus Cavernosum Smooth Muscle in Rats. PLOS ONE. 12 , e172191 (2017). doi: 10.1371/journal.pone.0172191 28245285
9 Wang G. C. et al . Corpus Cavernosum Smooth Muscle Cell Dysfunction and Phenotype Transformation are Related to Erectile Dysfunction in Prostatitis Rats with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J INFLAMM-LOND. 17 , 2 (2020). doi: 10.1186/s12950-019-0233-z 31911760
10 Zhao F. , Ye M. Y. , Zhao J. F. & Lu B. D. [Henotypic Modulation of Corporal Cavernosum Smooth Muscle Cells and Erectile Dysfunction: Advances in Studies]. Zhonghua Nan Ke Xue. 24 , 927–932 (2018). 32212450
11 Sullivan C. J. et al . Microarray Analysis Reveals Novel Gene Expression Changes Associated with Erectile Dysfunction in Diabetic Rats. PHYSIOL GENOMICS. 23 , 192–205 (2005). doi: 10.1152/physiolgenomics.00112.2005 16118269
12 Schalla M. A. et al . Nucb2/Nesfatin-1 ‐ Inhibitory Effects On Food Intake, Body Weight and Metabolism. PEPTIDES. 128 , 170308 (2020). doi: 10.1016/j.peptides.2020.170308 32229144
13 Stengel A. , Goebel M. & Tache Y. Nesfatin-1: A Novel Inhibitory Regulator of Food Intake and Body Weight. OBES REV. 12 , 261–271 (2011). doi: 10.1111/j.1467-789X.2010.00770.x 20546141
14 Ozturk O. G. Effects of Nesfatin-1 On Food Intake and Hyperglycemia. J AM COLL NUTR. 39 , 345–351 (2020). doi: 10.1080/07315724.2019.1646678 31369353
15 Fan Z. , Dong J. , Mu Y. & Liu X. Nesfatin-1 Protects Against Diabetic Cardiomyopathy in the Streptozotocin-Induced Diabetic Mouse Model Via the P38-Mapk Pathway. BIOENGINEERED. 13 , 14670–14681 (2022). doi: 10.1080/21655979.2022.2066748 35818327
16 Irannejad A. et al . Association of Peripheral Nesfatin-1 with Early Stage Diabetic Nephropathy. Pathophysiology. 24 , 17–22 (2017). doi: 10.1016/j.pathophys.2016.12.001 28038936
17 Turan M. & Turan G. Immunoreactivity of Icam-1, Mmp-2, and Nesfatin-1 in Lens Epithelial Cells of Patients with Diabetes Mellitus with Or without Diabetic Retinopathy. EUR J OPHTHALMOL. 32 , 255–262 (2022). doi: 10.1177/1120672120966559 33100052
18 Deniz R. et al . Nesfatin-1 and Other Hormone Alterations in Polycystic Ovary Syndrome. ENDOCRINE. 42 , 694–699 (2012). doi: 10.1007/s12020-012-9638-7 22367584
19 Hamed E. A. , Sayyed H. G. , Abbas A. M. , Gaber M. & Aleem H. Nesfatin-1, Dopamine, and Nadph Levels in Infertile Women with Polycystic Ovary Syndrome: Is there a Relationship Between their Levels and Metabolic and Hormonal Variables. J Reprod Infertil. 23 , 160–168 (2022). doi: 10.18502/jri.v23i3.10006 36415498
20 Prinz P. & Stengel A. Nesfatin-1: Current Status as a Peripheral Hormone and Future Prospects. CURR OPIN PHARMACOL. 31 , 19–24 (2016). doi: 10.1016/j.coph.2016.08.011 27589696
21 Kouidrat Y. et al . High Prevalence of Erectile Dysfunction in Diabetes: A Systematic Review and Meta-Analysis of 145 Studies. DIABETIC MED. 34 , 1185–1192 (2017). doi: 10.1111/dme.13403 28722225
22 Tamrakar D. , Bhatt D. S. , Sharma V. K. , Poudyal A. K. & Yadav B. K. Association Between Erectile Dysfunction and Type 2 Diabetes Mellitus. J Nepal Health Res Counc. 19 , 378–383 (2021). doi: 10.33314/jnhrc.v19i2.3394 34601534
23 Kim, S. C. Hyperlipidemia and Erectile Dysfunction. ASIAN J ANDROL. 2, 161–166 (2000). Escrig, A., Marin, R., Abreu, P., Gonzalez-Mora, J. L. & Mas, M. Changes in Mating Behavior, Erectile Function, and Nitric Oxide Levels in Penile Corpora Cavernosa in Streptozotocin-Diabetic Rats. BIOL REPROD. 66, 185–189 (2002).
24 Lin H. et al . Rapamycin Supplementation May Ameliorate Erectile Function in Rats with Streptozotocin-Induced Type 1 Diabetes by Inducing Autophagy and Inhibiting Apoptosis, Endothelial Dysfunction, and Corporal Fibrosis. J SEX MED. 15 , 1246–1259 (2018).30224017
25 Shafrir E. , Ziv E. & Mosthaf L. Nutritionally Induced Insulin Resistance and Receptor Defect Leading to Beta-Cell Failure in Animal Models. ANN NY ACAD SCI. 892 , 223–246 (1999). doi: 10.1111/j.1749-6632.1999.tb07798.x 10842665
26 Kapoor M. S. , Khan S. A. , Gupta S. K. , Choudhary R. & Bodakhe S. H. Animal Models of Erectile Dysfunction. J PHARMACOL TOX MET. 76 , 43–54 (2015). doi: 10.1016/j.vascn.2015.07.013 26279495
27 Sáenz De Tejada I. Molecular Mechanisms for the Regulation of Penile Smooth Muscle Contractility. INT J IMPOT RES. 14 , S6–S10 (2002). doi: 10.1038/sj.ijir.3900790 11850728
28 Schwartz B. G. , Economides C. , Mayeda G. S. , Burstein S. & Kloner R. A. The Endothelial Cell in Health and Disease: Its Function, Dysfunction, Measurement and Therapy. INT J IMPOT RES. 22 , 77–90 (2010). doi: 10.1038/ijir.2009.59 20032988
29 Owens G. K. , Kumar M. S. & Wamhoff B. R. Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and Disease. PHYSIOL REV. 84 , 767–801 (2004). doi: 10.1152/physrev.00041.2003 15269336
30 Lerner J. & Kratzer F. H. A Comparison of Intestinal Amino Acid Absorption in Various Avian and Mammalian Species. Comp Biochem Physiol A Comp Physiol. 53 , 123–127 (1976). doi: 10.1016/s0300-9629(76)80023-0 178
31 Lu Q. B. et al . Nesfatin-1 Functions as a Switch for Phenotype Transformation and Proliferation of Vsmcs in Hypertensive Vascular Remodeling. BBA-MOL BASIS DIS. 1864 , 2154–2168 (2018). doi: 10.1016/j.bbadis.2018.04.002 29627363
32 Tekin T. , Cicek B. & Konyaligil N. Regulatory Peptide Nesfatin-1 and its Relationship with Metabolic Syndrome. EURASIAN J MED. 51 , 280–284 (2019). doi: 10.5152/eurasianjmed.2019.18420 31692710
33 Burnett A. L. The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy. J CLIN HYPERTENS. 8 , 53–62 (2006). doi: 10.1111/j.1524-6175.2006.06026.x 17170606
34 Schalla M. A. et al . Nucb2/Nesfatin-1 ‐ Inhibitory Effects On Food Intake, Body Weight and Metabolism. PEPTIDES. 128 , 170308 (2020). doi: 10.1016/j.peptides.2020.170308 32229144
35 McAuley I. W. , Kim N. N. , Min K. , Goldstein I. & Traish A. M. Intracavernosal Sildenafil Facilitates Penile Erection Independent of the Nitric Oxide Pathway. J Androl. 22 , 623–628 (2001). 11451359
36 Shukla N. , Jones R. , Persad R. , Angelini G. D. & Jeremy J. Y. Effect of Sildenafil Citrate and a Nitric Oxide Donating Sildenafil Derivative, Ncx 911, On Cavernosal Relaxation and Superoxide
37 Formation in Hypercholesterolaemic Rabbits. EUR J PHARMACOL. 517, 224–231 (2005).
38 Brioni J. D. et al . Activators of Soluble Guanylate Cyclase for the Treatment of Male Erectile Dysfunction. INT J IMPOT RES. 14 , 8–14 (2002). doi: 10.1038/sj.ijir.3900801 11896472
39 Mizusawa H. , Hedlund P. , Brioni J. D. , Sullivan J. P. & Andersson K. E. Nitric Oxide Independent Activation of Guanylate Cyclase by Yc-1 Causes Erectile Responses in the Rat. J UROLOGY. 167 , 2276–2281 (2002). 11956492
40 Zhu S. B. et al . Tgf-Beta1 Induces Human Aortic Vascular Smooth Muscle Cell Phenotype Switch through Pi3K/Akt/Id2 Signaling. AM J TRANSL RES. 7 , 2764–2774 (2015).26885273
41 Michelet X. et al . Metabolic Reprogramming of Natural Killer Cells in Obesity Limits Antitumor Responses. NAT IMMUNOL. 19 , 1330–1340 (2018). doi: 10.1038/s41590-018-0251-7 30420624
